Payment overview · 2025
General Payments
$290.88
7 reported records · 5 companies
Healthcare provider profile · identity verified
Rafael Khaim, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · NEW YORK, NY · NPI 1306048665
Verified facts
What the public records show
CMS Open Payments records show Rafael Khaim, NP received $290.88 in general payments during 2025 across 7 reported records.
ABBVIE INC. accounted for 43.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Lokelma.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Lokelma by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $125.00 | 43.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $81.41 | 28.0% | 3 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $34.39 | 11.8% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $30.08 | 10.3% | 1 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $20.00 | 6.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $270.88 | 6 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $59.66 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $34.39 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $30.08 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| PowerGlide Normalized: powerglide |
Device | Becton, Dickinson and Company | $20.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 224 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
224 | 69 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 1682 | 378 |
| Famotidine | Famotidine | 935 | 272 |
| Valganciclovir Hcl | Valganciclovir Hcl | 681 | 210 |
| Tamsulosin Hcl | Tamsulosin Hcl | 641 | 188 |
| Nifedipine Er | Nifedipine | 583 | 172 |
| Prednisone | Prednisone | 580 | 176 |
| Atorvastatin Calcium | Atorvastatin Calcium | 510 | 169 |
| Tacrolimus | Tacrolimus | 502 | 125 |
| Pantoprazole Sodium | Pantoprazole Sodium | 425 | 131 |
| Cinacalcet Hcl | Cinacalcet Hcl | 418 | 106 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 316 | 114 |
| Metoprolol Tartrate | Metoprolol Tartrate | 303 | 87 |
| Carvedilol | Carvedilol | 297 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 257 | 95 |
| Lokelma | Sodium Zirconium Cyclosilicate | 224 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 219 | 67 |
| Furosemide | Furosemide | 209 | 92 |
| Januvia | Sitagliptin Phosphate | 201 | 49 |
| Losartan Potassium | Losartan Potassium | 197 | 61 |
| Eliquis | Apixaban | 160 | 33 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 157 | 55 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 152 | 46 |
| Labetalol Hcl | Labetalol Hcl | 140 | 52 |
| Nystatin | Nystatin | 127 | 124 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 120 | 120 |
| Alcohol Pads | Alcohol Antiseptic Pads | 103 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 90 | 33 |
| Atovaquone | Atovaquone | 83 | 27 |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 82 | 25 |
| Entecavir | Entecavir | 80 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 80 | 26 |
| Novolog Flexpen | Insulin Aspart | 75 | 37 |
| Allopurinol | Allopurinol | 73 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 26 |
| Procrit | Epoetin Alfa | 59 | 26 |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 57 | 25 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 55 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 53 | 18 |
| Lisinopril | Lisinopril | 47 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 45 | 21 |
| Calcitriol | Calcitriol | 43 | 17 |
| Finasteride | Finasteride | 43 | 12 |
| Clonidine Hcl | Clonidine Hcl | 42 | 20 |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 41 | suppressed |
| Zarxio | Filgrastim-Sndz | 41 | 20 |
| Tradjenta | Linagliptin | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 31 |
| Isoniazid | Isoniazid | 38 | 16 |
| Gabapentin | Gabapentin | 37 | 16 |
| Simvastatin | Simvastatin | 37 | 16 |
| Omeprazole | Omeprazole | 36 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 35 | 18 |
| Dapsone | Dapsone | 35 | 12 |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 34 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 31 | suppressed |
| Potassium Chloride | Potassium Chloride | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 27 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 26 | 23 |
| Envarsus Xr | Tacrolimus | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 23 | 13 |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Clonidine | Clonidine | 21 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Metformin Hcl | Metformin Hcl | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Repaglinide | Repaglinide | 18 | 11 |
| Mycophenolic Acid | Mycophenolate Sodium | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | 15 |
| Juluca | Dolutegravir/Rilpivirine | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 14 |
| Cephalexin | Cephalexin | 14 | 11 |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Trulicity | Dulaglutide | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 13 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 12 | suppressed |
| Cyclosporine Modified | Cyclosporine, Modified | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $290.88 · 7 records | ABBVIE INC. | ACTHAR, DUPIXENT, FARXIGA, LOKELMA, PowerGlide, UBRELVY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Lokelma play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error